The influence of ADRB1 polymorphisms on blood pressure and heart rate response to beta-blocker therapy in the treatment of acute coronary syndrome (ACS) has received limited attention, particularly in the Egyptian population. This evidence concerns the gene ADRB1 and acute coronary syndrome.